Background National guidelines recommend bisphosphonates for secondary prevention of osteoporotic fractures; however, poor compliance may result in sub-optimal prevention. Objective This study reports the feasibility of using GP electronic records to identify poorly compliant post-menopausal women who may be at increased risk of fragility fractures. Design Cross-sectional study of general practice computer records. Subjects Women over 45 years, registered in 29 practices across England with a total population of approximately 200,000. Methods MIQUEST (Morbidity Information Query and Export Syntax) a data extraction application was used to extract prescription, diagnostic data and probable fragility fractures (hip, vertebral, wrist). All women >45 years who received a first prescription for a weekly bisphosphonate (alendronate or risedronate) at least a year before data extraction were identified. Each record was examined to determine the number of days of prescribed treatment. Results Of 97992 registered women, 44% (42734) 
is poor, putting patients at risk. Bisphosphonates are known to increase bone mineral density (BMD) in the lumbar spine and hip and this appears to be clinically significant, in that new vertebral fractures, non-vertebral fractures and hip fracture rates are all reduced [1] [2] [3] [4] . However, compliance with bisphosphonates is known to be poor [5, 6] . Further, poor compliance translates into reduced bone mineral density (BMD) [7] increased hospitalisation and fracture rates [8, 9] . Compliance can be quantified using the medicines possession ratio (MPR); the ratio of the number of days' supply to the length of the study period. For bisphosphonates an MPR under 80% is associated with increased fracture risk [8, 10] .
The UK national guidelines recommend the use of bisphosphonates for the secondary prevention of fragility fractures in women with osteoporosis [11] . The guidance recommends the use of bisphosphonates in women 75 years and over, who have had a fracture without the need for measurement of BMD for those between 65 and 74 after measurement of BMD and in younger women if they have additional risk factors. In theory these patients should be easy to find from general practice computer records. Although computerisation is ubiquitous in UK general practice, osteoporosis data recording is variable [12] . Repeat prescribing data are generally complete and reliable [13] . However, in osteoporosis, diagnostic data are poor and there are technical problems which prevent the easy recording of dual X-ray densitometry (DXA) scan results [14] .
We carried out this study to investigate the feasibility of using routinely collected computer data to improve the quality of care for people with osteoporosis and help practices implement the new national guidelines. We decided to test the feasibility of identifying women who do not persist with bisphosphonate therapy, especially those with a likely fragility fracture or a pre-existing computer diagnosis of osteoporosis.
Method
We recruited a sample from practices who had participated previously in PCDQ (Primary Care Data Quality) programmes [15, 16] . We excluded practices who had been involved in previous PCDQ osteoporosis studies [12, 17] as this may have improved their osteoporosis computer data quality and we wanted our sample to be as representative as possible of "usual" UK practice. We invited practices from the north east and north west of England, London and the south east. We collected these data between March and May 2005.
We defined the dataset needed to answer our research question. The elements of the dataset were: demographic details, fracture recording, use of therapy to treat or prevent osteoporosis and the last twelve bisphosphonate prescriptions.
We used an established methodology to extract, aggregate, process, clean and analyse these data [18, 19] . We use MIQUEST (Morbidity Information and Export Syntax), a Department of Health sponsored data extraction application to extract anonymous data from general practice computer systems [20] .
We analysed the age-sex distribution of the population and compared it to the 2001 census population so that we could standardise prevalence rates. We analysed in detail data for women >45 years, in line with other investigators methods [21, 22] .
We looked at the types and age-distribution of fracture recording. We made the assumption that all fractures of wrist, hip and spine occurring over age 45 years were likely to be fragility fractures. We also included codes for fragility fracture. We separately searched the different sections of the clinical coding hierarchy (the UK uses Read codes) to identify the relevant events.
We identified the types of therapy prescribed for osteoporosis, including hormone replacement therapy; though recognising that the latter has a wide range of other indications. We included prescription data for any bisphosphonates with a licence for the treatment of osteoporosis. For technical reasons our extraction included pamidronate, ibandronate, clodronate and zoledronate, because these are included in the bisphosphonate coding hierarchy. These drugs are indicated for treatment of the pain from bone secondary cancer, they were excluded from our results. However, one of these, ibandronate, was in the process of obtaining a product licence for the treatment of osteoporosis. As none of the small number of patients on ibandronate had been prescribed over a year's therapy they were excluded from our results.
Finally, we examined the compliance with weekly bisphosphonates, alendronate and risedronate, over a oneyear period. We did this by analysing the last 12 prescriptions issued. Our previous studies indicated that these medications were never prescribed for less than one month and usually for two to six months at a time [12, 17] . We therefore felt that collecting data about the last 12 prescriptions would ensure we had data for at least a year. We set a cut off that all of these 12 prescriptions must have been issued more than 180 days (six months) before the data were extracted, so we would most likely capture fracture data recorded later when hospital discharge information came through.
We used the SPSS (Statistical Package for Social Sciences) to measure the number of days of therapy prescribed in the latest year of therapy. All the quantity elements were converted into the number of days of therapy. We did this by converting one "original pack" into the pack size defined in the British National Formulary and converting this into day therapy. The SPSS vector command was used to reorder the triplet of information we held about each prescription (drug code, date and quantity). The days prescribed for each patient for the time period between 18 months before (420 days) and six months (180 days) before data collection were then calculated.
We then calculated the percentage of people who complied for 12 months the median duration of therapy of those who did not persist for 12 months and the percentage of patients with a medicine possession ratio (MPR) of less than 80% (i.e., they collected prescriptions for less than 80% of a year:<288 days). To see if there was any relationship between compliance and a previous fragility fracture, we subsequently looked at the categories of compliance. Compliance of <50% is described as poor, 50-79% medium, 80-90% good, >90% excellent.
Finally, we looked to see whether a greater or lesser proportion of women >45 years with likely fragility fractures were persisting with their bisphosphonate therapy and whether people with multiple fractures were more likely to be compliant.
Statistical methods Mean is used to describe normally distributed variables, median and interquartile ranges (IQR) to describe variables which are not normally distributed. Chi-square (X 2 ) tests were performed to determine whether any changes in proportion were statistically significant.
Ethics Central ethics approval was granted for this study.
Results
Our sample had an age-sex profile close to the national average. The combined population from 29 practices was 195,910. The practices range in size from 1,817 to 13,693 (mean list size 6,756, median 7,127, IQR 2,325). Osteoporosis diagnosis recording rate was 1.08% (n=2,107), with a male-female recording ratio of 1:8 (males n=230; females n=1,877).
In women over 45 years old (n=42,734), the recorded prevalence was 4.31% (n=1,843). The standardised recorded prevalence of a diagnosis of osteoporosis using the 2001 census was 1.03%. The recorded prevalence of osteoporosis was variable between practices the prevalence varied from 0.00% to 2.50%, (median 0.93% IQR 0.74%).
The recorded prevalence of fractures increased with age. In males it was higher in younger men, but the converse applied in older women. The recording of fractures in males under 45 years had a higher fracture rate than females (M <45 yrs 1.67%; F <45 yrs 1.05%), but in women over 45 years old the prevalence of fractures is much greater (M ≥45 yrs 3.39%; F≥45 yrs 5.90%), these differences in proportion are statistically significant (Chi-square test p<0.001). The difference in fracture rates gets larger with increasing age (Table 1) .
A wide range of therapies for osteoporosis are used in the study practices and the numbers prescribed treatment greatly exceed the numbers with a diagnosis of osteoporosis (n=2,107). Therapies used include hormone replacement therapy (HRT; n= 9,865), calcium and vitamin D (n=4,771), bisphosphonates (n=2,977), selective estrogen receptor modulators (SERM; n=252) and calcitonin (n=20). The female to male ratio of drug therapy was 13:1 (Female 16614, Male 1271) ( Table 2) .
The weekly formulations of the bisphosphonates, alendronate and risedronate account for the majority of current therapy. We found that about half as many patients had been on daily formulations of bisphosphonates, compared with the weekly formulations (daily n=907, weekly n=2,064). However, a small proportion of the people persisted in taking a daily bisphosphonate, 11.26% (262/ 2326), at the end of the study. Bisphosphonates which at the time of the study were not indicated for use in osteoporosis (clodronate, pamidronate, ibandronate, tiludronate and andzoedronate) accounted for less than 1% of prescriptions for bisphosphonates.
3.0% (1286/42734, mean age 72 years, IQR 17 years) received a prescription for a weekly bisphosphonate in the 360-day period prior to data extraction with a mean duration of treatment 231 days, median duration of treatment, 267 days, 25%tile 112 days, 75%tile 336 days, IQR 224 days). In females over 45 years (n=42,734) approximately three times as many were taking weekly alendronate (n=1,297; 3.0%) compared with risedronate (n=458; 1.1%).
1,286 patients had 12 or more prescriptions for (alendronate 959, risedronate 327; ratio 2.93:1). For these 1,286 individuals we could calculate a medicines possession ratio (MPR). We found that 45% (584/1,286) had an MPR ≥80% who we labelled "compliant". A slightly higher proportion of those taking alendronate (47.0%, 451/959) were compliant compared with risedronate (40.7%, 133/327); these differences are of borderline significance (Pearson Chisquare: p=0.046.) We also noted that some women collected too many prescriptions. 27.6% (161/584) collected excess prescriptions and that 3.6% (21/584) had an MPR of over 120%.
The level of compliance was not evenly spread across the four categories of compliance. Most women either had excellent compliance (MPR >90%) or poor compliance (MPR <50%), with relatively few in the medium (MPR 50-79%) or good (MPR 80-90%) category (Fig. 1) . We found a similar pattern in men (data not shown).
Females over 45 years with a recording of a fracture are no more likely to be compliant with their weekly bisphosphonate therapy (alendronate or risedronate) than those without a fracture. 23% (294/1,286) of compliant people have had fracture; the compliant group have a fracture rate of 21% (123/584) compared with 24% (171/ 702) in the non-compliant group. These proportions are not significantly different (Pearson Chi-square =0.16). Multiple fractures were also not associated with improved compliance with bisphosphonates, it appears that women were generally poor or excellent in complying with therapy with relatively few in the intermediate groups (Fig. 1) .
A fracture was found to be recorded in 27% (183/684) of the people with a diagnosis of osteoporosis who were also prescribed a weekly bisphosphonate. Those with a diagnosis of osteoporosis are much more likely to have fracture than those who have not (27% compared with 19%) and this difference in proportion is statistically significant (Chisquare p<0.001). -69  3413  766  595  85  3  70-79  999  1016  814  79  4  80-89  180  908  634  24  6  90+  17  282  120  0  2  Total  9837  3959  2552  251  15 Based on these results a practice of 10,000 list size looking to implement national guidance on osteoporosis would expect to find:
-37 post menopausal women who are not compliant to therapy (MPR <80%) and one post menopausal women using too much medication. -Nine women over 45 with a fracture who are not compliant to bisphosphonates; three of whom would be aged 65 to 74 and five 75 years or older. 
Discussion

Principal findings
There is scope to improve the general practice management of osteoporosis by identifying non-compliant patients using computer searches. Many patients' quality of care falls outside national guidelines. Less than half of women prescribed bisphosphonates collect sufficient prescriptions to be compliant with their therapy. We also noted that a proportion collect too many prescriptions. People who have had a fracture recorded are no more likely to be compliant with their therapy than those without a fracture and multiple fractures make patients no more likely to comply. Computer data has the potential to identify people with osteoporosis who are not compliant to therapy. The numbers of people identified by such searches are probably manageable within general practice.
Implications for practice
Practices could use computer searches to identify their noncompliant patients and those who are apparently collecting too many scripts. Additional input may lead to improvement in compliance to therapy. This might take the form of a telephone consultation, a nurse visit, or a review by a pharmacist as part of a medicines management programme or a consultation with their general practitioner. This approach could also be used as a method to implement national guidance on the secondary prevention of fractures in osteoporosis [11] . Practices with poor data quality should improve their diagnostic recording and see that fractures are coded and entered into the computer record.
Limitations of the study
Osteoporosis diagnostic data remains incomplete and it is likely that fracture recording remains an under-estimate of true prevalence. Our assumptions that women over 45 years are "postmenopausal" and fractures in older women are likely to be osteoporotic are inevitably oversimplifications. Sanders et al. found that only 71% and 80% of pelvic and hip fractures, respectively, were truly osteoporotic [23] . The study was also limited by our ability to only extract structured data and the confused way that fractures and any DXA scan results are stored within the clinical record. We only looked at the structured or "coded" data in the clinical computer record. We did not extract free text or check any paper notes, hospital letters or reports. The clinical coding system has limitations: no codes for "fragility fracture" exist and it is impossible in the most used clinical computer system to enter negative numbers-making any recording of "T-scores" impossible to interpret as they are all positive numbers [12, 14] . This method may have overestimated the level of compliance, as we cannot be certain that the medications prescribed were actually taken. We did not investigate HRT compliance because this therapy has a range of indications other than the treatment of osteoporosis.
Comparison with the literature
Poor compliance is a problem with many long-term medications and there is no single effective strategy to overcome this. Monitoring use of therapy, reminders to collect prescriptions and reducing the frequency of dosage have all been shown to be useful, but none provide the complete solution to this problem [24, 25] . Others have found similarly poor levels of compliance to bisphosphonate therapy [8] . Osteoporosis and occurrence of fractures are under-recorded compared to rates recorded in the literature [26] [27] [28] this is likely due to poor computer data quality [12, 14, 17] . It is possible that including practices in a feedback loop will prove as effective in raising standards in this area as we have found in heart disease [16] .
Call for further research
Studies are needed to develop interventions that result in improvements in data quality and the quality of care in osteoporosis. Further studies, with more complete datasets, are needed to evaluate whether there truly are differences in compliance between the different bisphosphonates.
Conclusions
Whilst computer searches will not identify everyone who might benefit from bisphosphonate therapy, they enable a start to be made on identifying a high risk population and implementing national guidelines. A pragmatic place to start improving the quality of osteoporosis management would be to utilise existing information technology to find non-compliant patients; especially those who have pre-existing fractures.
